Bispecific Antibodies in Gastric Cancer Therapeutics: New Hope for High Efficacy and Tolerability

Ioannis A. Voutsadakis

PDF(279 KB)
For Authors|For Editors|For Reviewers
PDF(279 KB)
Discovery Medicine ›› 2025, Vol. 37 ›› Issue (198) : 1416-1421. DOI: 10.24976/Discov.Med.202537198.123
Commentary

Bispecific Antibodies in Gastric Cancer Therapeutics: New Hope for High Efficacy and Tolerability

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 37(198): 1416-1421 https://doi.org/10.24976/Discov.Med.202537198.123

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(279 KB)

Accesses

Citation

Detail
Sections
Recommended
Follow Us on
Copyright © 2026.
By using this website, you agree to our Terms & Conditions and Privacy Policy.  
  • Disclaimer
    The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    • /

    〈 〉